内容紹介
Summary
Epidermal growth factor receptor tyrosine kinase inhibitor(EGFR-TKI)is the first choice for the treatment of EGFR mutation-positive advanced non-small cell lung cancer(NSCLC). There have been few reports on the efficacy and safety of gefitinib in elderly patients with EGFR mutation-positive advanced NSCLC. We retrospectively assessed the efficacy and safety of gefitinib as first-line chemotherapy in 22 patients with advanced NSCLC aged 75 years or older and who were treated with gefitinib. The response rate was 81.8%, and the disease control rate was 95.5%. The median progression-free survival time was 14.2 months, and the median survival time was 30.7 months. The common adverse events were skin toxicities(50.0%), liver dysfunction(18.2%), and diarrhea(18.2%). The dose of gefitinib was reduced in 36.3% of the patients, and the treatment of gefitinib was discontinued in 18.2% of the patients. Gefitinib is effective and safe for elderly patients with advanced NSCLC.
要旨
上皮成長因子受容体チロシンキナーゼ阻害剤(EGFR-TKI)はEGFR遺伝子変異陽性進行非小細胞肺癌(NSCLC)において第一選択であるが,高齢者に対するgefitinibの有効性や安全性を検討した報告は少ない。当院で75歳以上の高齢者に対し,初回化学療法としてgefitinib 250 mgを投与した22例を後方視的に検討した。奏効率81.8%,病勢制御率95.5%,無増悪生存期間14.2か月,全生存期間中央値は30.7か月であった。皮膚毒性50.0%,肝機能障害18.2%,下痢を18.2%に認め,有害事象による減量36.3%,中止を18.2%で要した。高齢者進行NSCLCに対してgefitinibは有効であり,有害事象も耐用可能と考えられた。
目次
Epidermal growth factor receptor tyrosine kinase inhibitor(EGFR-TKI)is the first choice for the treatment of EGFR mutation-positive advanced non-small cell lung cancer(NSCLC). There have been few reports on the efficacy and safety of gefitinib in elderly patients with EGFR mutation-positive advanced NSCLC. We retrospectively assessed the efficacy and safety of gefitinib as first-line chemotherapy in 22 patients with advanced NSCLC aged 75 years or older and who were treated with gefitinib. The response rate was 81.8%, and the disease control rate was 95.5%. The median progression-free survival time was 14.2 months, and the median survival time was 30.7 months. The common adverse events were skin toxicities(50.0%), liver dysfunction(18.2%), and diarrhea(18.2%). The dose of gefitinib was reduced in 36.3% of the patients, and the treatment of gefitinib was discontinued in 18.2% of the patients. Gefitinib is effective and safe for elderly patients with advanced NSCLC.
要旨
上皮成長因子受容体チロシンキナーゼ阻害剤(EGFR-TKI)はEGFR遺伝子変異陽性進行非小細胞肺癌(NSCLC)において第一選択であるが,高齢者に対するgefitinibの有効性や安全性を検討した報告は少ない。当院で75歳以上の高齢者に対し,初回化学療法としてgefitinib 250 mgを投与した22例を後方視的に検討した。奏効率81.8%,病勢制御率95.5%,無増悪生存期間14.2か月,全生存期間中央値は30.7か月であった。皮膚毒性50.0%,肝機能障害18.2%,下痢を18.2%に認め,有害事象による減量36.3%,中止を18.2%で要した。高齢者進行NSCLCに対してgefitinibは有効であり,有害事象も耐用可能と考えられた。